Eton Pharmaceuticals, Inc. ETON
At closeNov 10, 2026, 5:33 PM EST
After hours · Nov 10, 5:33 PM ET
- YTD
- +299.41%
- 1 year
- +299.17%
- Market cap
- 1.95B
- Revenue (ttm)
- 141.06M
- Profit margin
- 35.35%
- EPS (ttm)
- 1.54
- Shares out
- 28.84M
- P/E ratio
- 43.86
- Forward P/E
- 20.44
- YTD return
- +299.41%
- 1-year return
- +299.17%
- Volume
- 1.18M
- Avg volume
- 594.19K
- Open
- 63.63
- Previous close
- 64.35
- Day's range
- 63.63 – 68.38
- 52-week range
- 14.27 – 68.38
- Beta
- 0.83
- Analysts
- Strong Buy
- Price target
- 78.00 (+15.5%)
- Earnings date
- Mar 18, 2027
5D +15.54 (+29.88%)
Key statistics
- Enterprise value
- 1.82B
- PEG ratio
- 0.00
- Price / sales
- 13.81
- Price / book
- 22.40
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 157.90%
- Free cash flow
- 13.96M
- Total cash
- 55.63M
- Total debt
- 24.33M
- Return on equity
- 90.62%
- Short % of float
- 9.29%
- 50-day average
- 54.89
- 200-day average
- 36.85
Analyst view
Consensus: strong buy
- Target (low)
- 70.00
- Target (mean)
- 78.00
- Target (high)
- 82.00
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 18, 2027
Expected Mar 18, 2027. Consensus EPS estimate 0.68.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 18, 2027 | Mar 30, 2027 | 0.38 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | 0.3125 | 0.50 | +0.19 | +60.00% |
| Aug 13, 2026 | Jun 30, 2026 | 0.1898 | 0.35 | +0.16 | +84.40% |
| May 14, 2026 | Mar 31, 2026 | 0.10 | 0.05 | -0.05 | -50.00% |
| Mar 19, 2026 | Dec 31, 2025 | 0.12 | 0.05 | -0.07 | -58.33% |
| Nov 6, 2025 | Sep 30, 2025 | 0.16 | -0.07 | -0.23 | -143.75% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | B. Riley Securities | main | Buy | Buy |
| Nov 6, 2026 | Canaccord Genuity | main | Buy | Buy |
| Nov 6, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 14, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 14, 2026 | Canaccord Genuity | main | Buy | Buy |
| Aug 14, 2026 | B. Riley Securities | reit | Buy | Buy |
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- etonpharma.com
News
B. Riley Securities Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $81 
Canaccord Genuity Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $80 - HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $80
12 Health Care Stocks Moving In Friday's Pre-Market Session 
Eton Q3 Earnings Call Highlights Growth and Pipeline Expansion 
Why Cloudflare Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket 
Eton Pharmaceuticals Q3 Earnings Call Highlights 
Eton Pharmaceuticals Q3 2026 Earnings Call Transcript 
Eton Pharmaceuticals Announces Its ET-700 Zing Acetate Formulation Shows Lower Rate Of Drug Related Adverse Events In Pilot Trial Than GALZIN; No Serious Adverse Events Seen 
Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London
Your note
Sign in to keep a note on ETON — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS JENNIFER MCKIE | Director | Sale | Jun 16, 2026 | 0 |
| BRYNJELSEN SEAN E | Chief Executive Officer | Sale | Aug 19, 2026 | 961,194 |
| GRUBER JAMES R | Chief Financial Officer | Sale | Aug 19, 2025 | 204,753 |
| KREMPA DAVID | Officer | Sale | Oct 5, 2026 | 43,381 |
| MAIER PAUL V | Director | Sale | Aug 27, 2026 | 59,745 |
| OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jul 13, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Opaleye Management Inc. | 9.92% | 2,860,000 | 193.16M | Jun 29, 2026 |
| EcoR1 Capital, LLC | 7.53% | 2,171,938 | 146.69M | Jun 29, 2026 |
| Blackrock Inc. | 6.57% | 1,895,833 | 128.04M | Jun 29, 2026 |
| Nantahala Capital Management, LLC | 4.08% | 1,175,951 | 79.42M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.39% | 976,570 | 65.96M | Jun 29, 2026 |
| Morgan Stanley | 2.66% | 767,972 | 51.87M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Russell 2000 ETF | 2.40% | 690,942 | 46.67M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.37% | 684,821 | 46.25M | Jun 29, 2026 |
| OBERWEIS FUNDS-Oberweis Micro-Cap Fund | 1.68% | 483,900 | 32.68M | Jun 29, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.52% | 439,150 | 29.66M | Aug 30, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.01% | 292,342 | 19.74M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.94% | 271,079 | 18.31M | Jun 29, 2026 |